Hello, and welcome to the Q1 2025 Teva Pharmaceutical Industries Limited Earnings Conference Call. My name is Alex, and I’ll be coordinating the call today. [Operator Instructions]. […] ...

Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to ...

For an accessible version of this Press Release, please visit On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of ...

For an accessible version of this Press Release, please visit www.tevapharm.com (1) Revised 2025 outlook now includes no contribution from the Japan BV after Q1 and continues to include a full ...

Almost exactly three years after agreeing on a $2.6 billion deal to acquire Aimmune Therapeutics and its peanut allergy therapy Palforzia, food group Nestle has sold off the business. This morning ...

As of 4:50:12 PM GMT+2. Market Open.